Description of Parkinson's disease as a clinical syndrome.
about
Effects of Resistance Training on Measures of Muscular Strength in People with Parkinson's Disease: A Systematic Review and Meta-AnalysisChondroitin sulfate proteoglycans in the nervous system: inhibitors to repairLeucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domainMitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cellsThreonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagyThe blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studiesPharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensorDopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric DisordersA Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future ProspectsDeep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's DiseaseNeuroinflammation in Parkinson's disease and its potential as therapeutic targetDeconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purposeApplications of Induced Pluripotent Stem Cells in Studying the Neurodegenerative DiseasesMovement and Other Neurodegenerative Syndromes in Patients with Systemic Rheumatic Diseases: A Case Series of 8 Patients and Review of the LiteratureAdult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticityNeuroantibody biomarkers: links and challenges in environmental neurodegeneration and autoimmunityInflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link?Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohortStructural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contactsLipid pathway alterations in Parkinson's disease primary visual cortexAcupuncture enhances the synaptic dopamine availability to improve motor function in a mouse model of Parkinson's diseasePathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic miceThe Solution Structure and Dynamics of Full-length Human Cerebral Dopamine Neurotrophic Factor and Its Neuroprotective Role against α-Synuclein Oligomers.Listener Perception of Monopitch, Naturalness, and Intelligibility for Speakers With Parkinson's Disease.The marmoset as a model of aging and age-related diseases.Startle reflex hyporeactivity in Parkinson's disease: an emotion-specific or arousal-modulated deficit?Spinal cord stimulation restores locomotion in animal models of Parkinson's diseaseAssessment of Parkinson disease manifestations.Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's diseaseSmartphone- and internet-assisted self-management and adherence tools to manage Parkinson's disease (SMART-PD): study protocol for a randomised controlled trial (v7; 15 August 2014).A visual review of the interactome of LRRK2: Using deep-curated molecular interaction data to represent biology.Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease.DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson's diseaseBiophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats.Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease.
P2860
Q21131738-913C3872-BC00-4688-9F83-F5AE1716A11EQ21284516-0090AB05-1F39-40FB-9300-C1BDB8AE068DQ24293453-601D0E7F-C589-4683-97CC-6F88118719AFQ24300095-4DE0EFB2-1C36-4253-A110-72BCDBE86D1EQ24307769-B01C1F89-0579-4AFC-A39D-5044CDCA220BQ24605294-090353DA-DBFC-4E2B-81D5-2A1AFCD9A644Q24627304-A4084C86-4536-4D7B-B63E-15597014170FQ24815335-4C9CDC41-3BFF-493D-A0AB-67B7481D12E0Q26745690-6FB6FF6B-755D-4903-9E06-19E2F29719C1Q26746033-9AFD4FF6-EF06-48C8-8C15-43A3A1A56463Q26747575-AD2B22E8-0F9C-454D-B8B9-E84C071E3DA6Q26783305-D51397F2-1202-47E5-9690-A7A974E7A46EQ26785491-21D3C3F1-0B0F-4E05-B359-7B68BB68459AQ26799331-F07FBE18-B961-4760-9CBC-3032CC46188CQ26801152-24FBD07D-46C5-4DFB-89A7-6AE485525C68Q26862840-E3B28EF2-B8A0-4918-B7A2-B660D00DC00BQ27010245-A542D5BC-9502-4C8C-B717-B91F6C3EDBDBQ27022728-EBC821C0-FF9B-4F60-B74E-FD0FCC4592BAQ27308109-BBD74718-C5D6-4783-A62D-557A804D5487Q28076121-D3C0CED3-BFF2-4E01-BBB3-0D71771685E4Q28116245-198EA4A0-A0A4-417A-9B56-185C37A6DB76Q28386548-9757B394-4010-4B28-87FE-7157EF728651Q28394023-0689C53B-912C-42D2-AFAA-08B631332F46Q29620597-EF592055-1CE6-459F-A99C-4AE1F2E673CBQ30376382-95D193C8-E308-41E2-BB73-D6E399D925BBQ30390464-9E18D307-B206-4425-884D-786259DB11A9Q30449246-C3767FC3-399D-4744-9516-AC08CAD0B547Q30480822-EAE99239-C10D-4FE0-9993-E287D66B77C0Q30487075-F7C4B99A-1F62-4204-98FD-6303E02CD7D0Q30495302-8E794D06-2856-471C-AD5A-EE632C953CBAQ30537842-2FA57CC9-678A-4854-8130-8FCDECDD56C7Q30612675-986CD6D4-65B7-474B-A149-A13C6B1E3BD8Q30887351-A1DE4A4E-E42B-451E-B5C2-DE233484DC7BQ31109638-65D61905-03BA-4829-8A46-737B6C0F6F36Q33326619-57E6B8D7-3BC2-4A8B-9928-89B4839A7BE3Q33353558-14934B90-A1EB-4280-B99E-4ECD847EB8F6Q33470625-7CC0C9FC-2F29-4F04-B626-70717603629DQ33553317-8ACCECD8-F432-4609-BFE2-B32E8F489A7FQ33577056-EBF23D5F-26D4-444B-87B6-A337441CD9E3Q33615747-2C1556D1-9779-42FD-B027-37D36A011B41
P2860
Description of Parkinson's disease as a clinical syndrome.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Description of Parkinson's disease as a clinical syndrome.
@ast
Description of Parkinson's disease as a clinical syndrome.
@en
type
label
Description of Parkinson's disease as a clinical syndrome.
@ast
Description of Parkinson's disease as a clinical syndrome.
@en
prefLabel
Description of Parkinson's disease as a clinical syndrome.
@ast
Description of Parkinson's disease as a clinical syndrome.
@en
P1476
Description of Parkinson's disease as a clinical syndrome
@en
P2093
Stanley Fahn
P356
10.1111/J.1749-6632.2003.TB07458.X
P407
P50
P577
2003-06-01T00:00:00Z